Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 5:26 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 2,391 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pancreatic Cancer Clear all
Recruiting Phase 2 Interventional

Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

NCT05776524
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic Adenocarcinoma
Interventions
Nab paclitaxel, Gemcitabine, TheraBionic
Drug · Device
Lead sponsor
THERABIONIC INC.
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Nov 2, 2026, 5:26 AM EST
Completed Phase 1Phase 2 Interventional Results available

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

NCT04068896
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
Interventions
NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane, NGM120 100mg with Gemcitabine and Abraxane, NGM120 100mg Q3W, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Nov 2, 2026, 5:26 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

NCT05736731
View directory record Official record
Conditions
Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
Interventions
A2B530, xT-Onco with HLA-LOH Assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Nov 2, 2026, 5:26 AM EST
Completed Phase 1Phase 2 Interventional Results available

CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas

NCT00540579
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Pomalidomide, Gemcitabine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Aurora, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Nov 2, 2026, 5:26 AM EST
Completed Phase 1 Interventional Results available

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02159989
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Solid Neoplasm
Interventions
Sapanisertib, Ziv-Aflibercept
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 2, 2026, 5:26 AM EST
Completed Phase 2 Interventional

Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer

NCT00004190
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, oxaliplatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
18
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Nov 2, 2026, 5:26 AM EST
Completed Phase 2 Interventional Results available

Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery

NCT00601627
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
panitumumab, capecitabine, fluorouracil, gemcitabine hydrochloride, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
281
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 173 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Nov 2, 2026, 5:26 AM EST
Terminated Phase 1 Interventional

FOLFIRINOX + NIS793 in Pancreatic Cancer

NCT05417386
View directory record Official record
Conditions
Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions
FOLFIRINOX, Oxaliplatin, Leucovorin, Irinotecan, 5-Fluorouracil (5-FU), NIS793, Chemoradiation, Capecitabine, Radiation Therapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
Colin D. Weekes, M.D., PhD
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Nov 2, 2026, 5:26 AM EST
Completed Phase 1 Interventional

Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer

NCT04106856
View directory record Official record
Conditions
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
Interventions
Hypofractionated Radiation Therapy, Losartan, Losartan Potassium
Radiation · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 2, 2026, 5:26 AM EST
Recruiting Phase 3 Interventional

Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?

NCT05720338
View directory record Official record
Conditions
Cyst of Pancreas, Pancreatectomy, Pancreas Neoplasm
Interventions
19 French Blake Drain
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 2, 2026, 5:26 AM EST
Completed Phase 2 Interventional

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

NCT00027638
View directory record Official record
Conditions
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome
Interventions
thalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Nov 2, 2026, 5:26 AM EST
Terminated Phase 2 Interventional

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

NCT00550004
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
RP101, Gemcitabine (1000 mg/m2)
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
16
States / cities
Tucson, Arizona • Beverly Hills, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Nov 2, 2026, 5:26 AM EST
Terminated Phase 1 Interventional

Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy

NCT03118349
View directory record Official record
Conditions
Pancreatic Carcinoma, Tumors That Express CA 19-9
Interventions
MVT-1075, MVT-5873
Drug
Lead sponsor
BioNTech Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Scottsdale, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Nov 2, 2026, 5:26 AM EST
Completed Phase 1Phase 2 Interventional Results available

Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas

NCT01128296
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Hydroxychloroquine, Gemcitabine
Drug
Lead sponsor
Amer Zureikat
Other
Eligibility
19 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Nov 2, 2026, 5:26 AM EST
Terminated Phase 2 Interventional Results available

Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer

NCT03599362
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Nivolumab + Cabiralizumab, Stereotactic Body Radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Nov 2, 2026, 5:26 AM EST
Completed Phase 1 Interventional

Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source

NCT03109041
View directory record Official record
Conditions
Pancreas Cancer, Cancer
Interventions
CivaSheet
Device
Lead sponsor
CivaTech Oncology
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Nov 2, 2026, 5:26 AM EST
Completed Phase 3 Interventional

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

NCT01360853
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
ON 01910.Na, Gemcitabine
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
30
States / cities
La Jolla, California • Palm Springs, California • Salinas, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Nov 2, 2026, 5:26 AM EST
Terminated Phase 2 Interventional Results available

Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery

NCT00833859
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
GTX (gemcitabine, docetaxel and capecitabine), stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Nov 2, 2026, 5:26 AM EST
Not listed Not applicable Interventional

Rectal Indomethacin to Prevent Acute Pancreatitis in EUS-FNA of Pancreatic Cysts

NCT05572788
View directory record Official record
Conditions
Pancreatic Cyst, Pancreatitis, Acute
Interventions
EUS-guided fine needle aspiration of pancreatic cysts
Procedure
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Nov 2, 2026, 5:26 AM EST
Not listed Phase 3 Interventional

Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

NCT00005869
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, rubitecan
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Dublin, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Nov 2, 2026, 5:26 AM EST
Completed Phase 1Phase 2 Interventional Results available

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

NCT00769483
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Adenocarcinoma
Interventions
MK-0646, Gemcitabine, Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Nov 2, 2026, 5:26 AM EST
Active, not recruiting Phase 1 Interventional

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

NCT05984602
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Canakinumab, Tislelizumab, Nab-Paclitaxel, Gemcitabine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 2, 2026, 5:26 AM EST
Completed Phase 1 Interventional

Rapamycin With Grapefruit Juice for Advanced Malignancies

NCT00375245
View directory record Official record
Conditions
Tumors, Neoplasm Metastasis
Interventions
Rapamycin (sirolimus), Grapefruit Juice
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Nov 2, 2026, 5:26 AM EST
Recruiting Phase 2 Interventional

Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial

NCT03322995
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
First-line Chemotherapy, Second-line Chemotherapy, Chemoradiation
Drug · Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Nov 2, 2026, 5:26 AM EST